Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - HEPSERA
Product / population
Adult oral adefovir for chronic hepatitis B; not a preferred-therapy recommendation
Renal method
Cockcroft-Gault CrCl using lean or ideal body weight; mL/min
Source revision
December 2018
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
GlobalRPh-hosted RX List · Adult oral adefovir for chronic hepatitis B; not a preferred-therapy recommendation
Renal method: Cockcroft-Gault CrCl using lean or ideal body weight; mL/min Source date: December 2018 Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Adult baseline renal impairment: 10 mg orally every 24 hours at CrCl >=50 mL/min, every 48 hours at 30-49, and every 72 hours at 10-29. Hemodialysis: 10 mg every seven days after dialysis. The table specifies Cockcroft-Gault with lean or ideal body weight.
No regimen is available below 10 mL/min without hemodialysis or for adolescents with renal insufficiency. These interval adjustments were not clinically validated for safety/effectiveness and were derived from pre-existing renal impairment; they may not apply when renal injury develops during treatment. Follow renal function and antiviral response closely. Peritoneal-dialysis removal was not evaluated.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.